COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
May 05, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000064.pdf 0001103021-20-000064.rtf 0001103021-20-000064.xls
Apr 29, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000060.pdf 0001103021-20-000060.rtf 0001103021-20-000060.xls
Apr 22, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000058.pdf 0001103021-20-000058.rtf 0001103021-20-000058.xls
Apr 17, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000056.pdf 0001103021-20-000056.rtf 0001103021-20-000056.xls
Apr 06, 2020	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193805-20-000454.pdf 0001193805-20-000454.rtf 0001193805-20-000454.xls
Mar 19, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0000919574-20-002503.pdf 0000919574-20-002503.rtf 0000919574-20-002503.xls
Mar 18, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000051.pdf 0001103021-20-000051.rtf 0001103021-20-000051.xls
Mar 18, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000052.pdf 0001103021-20-000052.rtf 0001103021-20-000052.xls
Mar 18, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000053.pdf 0001103021-20-000053.rtf 0001103021-20-000053.xls
Mar 18, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000054.pdf 0001103021-20-000054.rtf 0001103021-20-000054.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting January 15, 2021

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C. , Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty ...

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference November 20, 2020

RALEIGH, N.C. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey , Chief Executive Officer, and ...

BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18 November 11, 2020

RALEIGH, N.C. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now